Literature DB >> 9850065

Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398.

N Rioux1, A Castonguay.   

Abstract

Acetylsalicylic acid (ASA) is known to prevent cancer development, but its mechanism of action remains unclear. In this study, we compared the efficacies of this nonspecific cyclooxygenase (COX) inhibitor with N-[2-(cyclohexyloxy)-4-nitrophenyl]-methanesulfonamide (NS-398), a specific COX-2 inhibitor. COX-2-specific inhibitors are less toxic than ASA. Lung tumorigenesis was induced in A/J mice by the administration of the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in the drinking water for 7 weeks (weeks 0 to +7). Groups of 25 A/J mice were fed ASA (588, 294, 147, or 73 mg/kg diet) before and throughout the assay (weeks -2 to +23). ASA at a dose of 588 mg/kg diet was the most effective because it reduced lung tumor multiplicity by 53%. The preventive effect of ASA increased with the dose, being of 32, 30, and 44% for 73, 147, and 294 mg/kg diet, respectively. NNK increased plasma prostaglandin E2 (PGE2) basal levels by 413%, whereas ASA attenuated this elevation in a dose-response manner (r2 = 0.99). Plasma PGE2 levels in ASA + NNK-treated mice correlate with the logarithm of the number of tumors (r2 = 0.99). NS-398 inhibited lung tumor multiplicity by 34% and returned plasma PGE2 to basal levels observed in untreated mice. Among the NNK-exposed mice, ASA and NS-398 treatment decreased the mean of the lung tumor volumes. Incubation of 82-132 and LM2 murine lung tumor cells with ASA or NS-398 decreased cell proliferation by 50% at concentrations higher than 100 microM. Incubations of NNK with COX-1 and -2 produced both activation and detoxification products by alpha-carbon hydroxylation and N-oxydation pathways, respectively. Bioactivation of NNK was more extensive by COX-2 than COX-1. Anti-COX-1 and -2, arachidonic acid, ASA, and NS-398 inhibited NNK bioactivation by COX-1 and -2 from 22-49%. Our data suggest that NNK is bioactivated by COX-2 in lung tissues and that COX-2-specific inhibitors might be promising chemopreventive agents.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9850065

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

Review 1.  Crosstalk of oncogenic and prostanoid signaling pathways.

Authors:  Rolf Müller
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-15       Impact factor: 4.553

2.  Epstein-Barr virus protein can upregulate cyclo-oxygenase-2 expression through association with the suppressor of metastasis Nm23-H1.

Authors:  Rajeev Kaul; Subhash C Verma; Masanao Murakami; Ke Lan; Tathagata Choudhuri; Erle S Robertson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Early manifestations of NNK-induced lung cancer: role of lung immunity in tumor susceptibility.

Authors:  Seddigheh Razani-Boroujerdi; Mohan L Sopori
Journal:  Am J Respir Cell Mol Biol       Date:  2006-07-27       Impact factor: 6.914

4.  Suppressive oligodeoxynucleotides reduce lung cancer susceptibility in mice with silicosis.

Authors:  Christian Bode; Takeshi Kinjo; W Gregory Alvord; Dennis M Klinman
Journal:  Carcinogenesis       Date:  2014-01-08       Impact factor: 4.944

5.  Lung cancer chemoprevention with celecoxib in former smokers.

Authors:  Jenny T Mao; Michael D Roth; Michael C Fishbein; Denise R Aberle; Zuo-Feng Zhang; Jian Yu Rao; Donald P Tashkin; Lee Goodglick; E Carmack Holmes; Robert B Cameron; Steven M Dubinett; Robert Elashoff; Eva Szabo; David Elashoff
Journal:  Cancer Prev Res (Phila)       Date:  2011-07

6.  Regulation of cytokine-induced prostanoid and nitric oxide synthesis by extracellular signal–regulated kinase 1/2 in lung epithelial cells.

Authors:  Pamela L Rice; Bradley S Barrett; Jason M Fritz; Mary C Srebernak; Lori R Kisley; Alvin M Malkinson; Lori D Dwyer-Nield
Journal:  Exp Lung Res       Date:  2010-11       Impact factor: 2.459

7.  COX-2 overexpression and -8473 T/C polymorphism in 3' UTR in non-small cell lung cancer.

Authors:  Imtiyaz A Bhat; Roohi Rasool; Iqbal Qasim; Khalid Z Masoodi; Shabeer A Paul; Bashir A Bhat; Farooq A Ganaie; Sheikh A Aziz; Zafar A Shah
Journal:  Tumour Biol       Date:  2014-08-12

8.  The synergistic induction of cyclooxygenase-2 in lung fibroblasts by angiotensin II and pro-inflammatory cytokines.

Authors:  Takaya Matsuzuka; Kathryn Miller; Lara Pickel; Chiyo Doi; Rie Ayuzawa; Masaaki Tamura
Journal:  Mol Cell Biochem       Date:  2008-10-01       Impact factor: 3.396

9.  A novel sulindac derivative inhibits lung adenocarcinoma cell growth through suppression of Akt/mTOR signaling and induction of autophagy.

Authors:  Evrim Gurpinar; William E Grizzle; John J Shacka; Burton J Mader; Nan Li; Nicholas A Piazza; Suzanne Russo; Adam B Keeton; Gary A Piazza
Journal:  Mol Cancer Ther       Date:  2013-02-26       Impact factor: 6.261

10.  Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line.

Authors:  Alfred Haynes; Madhu Sudhan Shaik; Abhijit Chatterjee; M Singh
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.